SCHEMBL6164480

SCHEMBL6164480

CN(C)c1cc(NC(=O)OC(C)(C)C)c(N)cc1C#Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 3/20 0.39
PTPN6 P29350 2/20 0.39
PTPN1 P18031 1/20 0.39
PTPRB P23467 1/20 0.39
PTGES O14684 1/20 0.39
BRD9 Q9H8M2 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
CNR2 P34972 1/20 0.34
NPC1 O15118 3/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7140608 0.85 BRD9 (0.40) PTPN11PTGESBRD9RXFP1CNR2
SCHEMBL7138113 0.84 HSP90AA1 (0.40) PTPN11PTGESBRD9RXFP1CNR2
SCHEMBL7145926 0.83 AAK1 (0.41) PTPN11PTGESBRD9ALDH1A1AAK1
SCHEMBL6165164 0.83 NPC1 (0.38) PTPN11PTPN6PTPN1PTPRBPTGES
SCHEMBL7139941 0.83 ATR (0.38) PTPN11PTGESBRD9RXFP1CNR2
SCHEMBL6162611 0.82 TRPA1 (0.38) AAK1CTSLCTSBCTSS
SCHEMBL1706042 0.80 PTGES (0.43) PTPN11PTGESBRD9RXFP1CNR2
SCHEMBL7139886 0.80 PTGES (0.36) PTPN11PTGESBRD9CNR2MEN1
SCHEMBL7143096 0.80 PTGES (0.37) PTPN11PTGESBRD9RXFP1CNR2
SCHEMBL7145475 0.80 CTSS (0.38) PTPN11PTPN1PTGESAAK1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
EP-1379511-A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 PTPN11 3696/4885PTPN6 3872/4885PTPN1 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.